Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Pittsburgh
Lumos Pharma
Actuate Therapeutics Inc.
iOnctura
Merck Sharp & Dohme LLC
Chinese PLA General Hospital
Verastem, Inc.
Australasian Gastro-Intestinal Trials Group
Phanes Therapeutics
Immodulon Therapeutics Ltd
OHSU Knight Cancer Institute
Aravive, Inc.
Chinese PLA General Hospital
ETOP IBCSG Partners Foundation
OncoSec Medical Incorporated
Seagen Inc.
Ludwig-Maximilians - University of Munich
Brown University
H. Lee Moffitt Cancer Center and Research Institute
NYU Langone Health
Theriva Biologics SL
Mereo BioPharma
Halozyme Therapeutics
Incyte Corporation
Altor BioScience
Barts & The London NHS Trust
Celgene
Celgene
Universitaire Ziekenhuizen KU Leuven
SCRI Development Innovations, LLC
Stamford Hospital
Theriva Biologics SL
Incyte Corporation
Icahn School of Medicine at Mount Sinai
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Celgene
GERCOR - Multidisciplinary Oncology Cooperative Group
Celgene Corporation
Celgene Corporation
University of California, San Francisco
Kaiser Permanente
Veeda Oncology
Celgene Corporation